We developed a preclinical prostate cancer model to study the feasibility of adoptive immunotherapy for residual tumor following neo-adjuvant in situ adenoviral-vector-mediated interleukin 12 (AdIL-12) gene therapy. Splenocytes were obtained from mice with orthotopic 178-2 BMA metastatic mouse prostate cancers treated previously with AdIL-12, or a vector with the IL-12 genes plus the costimulatory gene B7-1 (AdIL-12/B7), or a control gene (Adbgal). The splenocytes were subsequently injected intravenously into syngeneic mice bearing orthotopic 178-2 BMA tumors generated 3 days previously. Significant orthotopic tumor growth suppression was achieved with splenocytes derived from mice whose tumors had been injected with AdIL-12 compared to splenocytes from control Adbgal mice (P ¼ 0.0005) and splenocytes from AdIL-12/B7-treated mice significantly suppressed spontaneous lung metastases compared to splenocytes from control mice (P ¼ 0.0356). Adoptive transfer of splenocytes from either AdIL-12 (P ¼ 0.004) or AdIL-12/B7 (P ¼ 0.009)-treated mice significantly prolonged survival relative to controls. Transfer of NK and tumor-specific CTL activities was detected and depletion of CD4 þ and CD8 þ T cells by in vitro antibody-mediated complement lysis of the splenocytes prior to injection abrogated the effects. Systemic IL-12 administration delivered by intramuscular AdIL-12 injection enhanced the antitumor effects of adoptive splenocyte transfer and boosted the CTL response. Our data provide evidence that this form of adoptive immunotherapy can enhance the effectiveness of neo-adjuvant in situ IL-12 gene therapy in cases of persistent malignancy.
Introduction
Men with clinically localized prostate cancer have conventional treatment options that include radical prostatectomy and irradiation but the ability of either to significantly reduce prostate cancer mortality has not been rigorously tested in controlled clinical trials. Indeed the high incidence of men with presumed prostate cancer recurrence based on rising serum prostate-specific antigen levels following either therapy 1 suggests that additional therapeutic options are warranted. One likely cause of recurrence is the presence of occult micrometastases at the time of treatment. In general, there is a relationship of tumor volume with metastatic progression, however, relatively small tumors that are confined to the prostate may also seed metastases. [2] [3] [4] [5] [6] In vivo experiments with the mouse prostate reconstitution model of prostate cancer also support these clinical observations. 7 Since neither radical prostatectomy nor radiation therapy offers effective antimetastatic benefits, novel adjuvant approaches, such as gene/immunotherapy, are warranted.
Results of preclinical studies and clinical trials using gene therapy for prostate cancer suggest that specific gene therapy approaches involving in situ delivery of immunomodulatory genes directly into localized prostate cancer lesions may generate effective antimetastatic activities. This in situ immunomodulatory gene therapy approach has been termed an active vaccine. 8 Initial studies with a direct cytotoxic approach, HSV-tk þ GCV, suggested that in situ gene therapy could generate an immune response in experimental systems. [9] [10] [11] Multiple clinical trials in men with this gene therapeutic approach have revealed necrosis within prostate cancer lesions in preference to adjacent normal prostatic tissues, 12 increased immune cells 12, 13 and, when combined with radiation, an increase in the frequency of biopsies without evidence of cancer. 14 Additional studies have confirmed that intraprostatic adenoviral vector-mediated HSV-tk followed by systemic GCV treatment leads to increased numbers of HLA DR þ CD8 þ T cells in the peripheral blood of treated men. 13, 15 We have also tested another active vaccine approach involving the immunomodulatory gene IL-12. Preclinical studies with an adenoviral vector containing the IL-12 genes (AdIL-12) in an orthotopic mouse prostate cancer model indicate that this therapy suppresses not only local tumors and also lung metastases and generates systemic immune activities such as NK cells. 16, 17 Based on these studies a clinical trial of in situ adenoviral vector-mediated delivery of IL-12 has recently been initiated in men with a biopsy confirmed, local prostate cancer recurrence.
Cell-based immunomodulatory therapeutic approaches for prostate cancer may also prove clinically useful; however, the lack of well-defined tumor antigens could be a major limitation to this approach. To this end we have shown that antitumor and antimetastatic prostate cancer therapy can also be initiated with AdIL-12-modified macrophage 18 or dendritic cells 19 injected directly into mouse prostate orthotopic tumors. We undertook the present studies to evaluate if the systemic activities generated following orthotopic delivery of AdIL-12 were transferable via immune cells contained in the spleen of treated animals. We demonstrate that adoptive transfer of splenocytes obtained from animals treated with in situ AdIL-12 gene therapy have therapeutic activities that involve CD4 þ and CD8 þ T cells. Interestingly, this activity can be increased by concurrent intramuscular (IM) AdIL-12 injections.
Materials and methods

Cells and adenoviral vectors
Growth of the mouse prostate cancer cell line 178-2BMA has been previously described. [18] [19] [20] The construction and purification of the adenoviral vectors AdIl-12, AdIL-12/ B7 and Adbgal have been described. [16] [17] [18] [19] 21 Mice Male 129/Sv mice were used at 12-16 weeks of age. All mice were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care, and all animal studies were conducted in accordance with the principles and procedures outlined in the NIH's Guide for the Care and Use of Laboratory Animals.
In situ gene therapy After trypsinization, 178-2 BMA cells were counted and resuspended in HBSS. For orthotopic tumor inoculation, syngeneic 129S/v mice were injected in the right lobe of the dorsolateral prostate with 5000 cells in 10 ml. The tumors were allowed to grow for 7 days, at which time the tumor volume was between 5 and 15 mm 3 . The optimal therapeutic doses of AdIL-12 16 (1 Â 10 8 PFU) and AdIL-12/B7 17 (5 Â 10 7 PFU) were directly injected into the established prostate tumors in a volume of 25 ml as previously described. 20 Adbgal (1 Â 10 8 PFU) was injected as a control.
Adoptive therapy
Splenocytes were obtained from mice treated with in-situ gene therapy 14 days after vector injection and cultured in RPMI 1640 containing 50 mM 2-mercaptoethanol with 10% heat-inactivated FBS and mouse IL-2 (20 U/ml, R&D systems, Minneapolis, MN) at 371C in a humidified atmosphere containing 5% CO 2 for 14-15 h. Nonadherent cells were collected and injected into the tail vain (1 Â 10 7 cells/mouse in 100 ml of HBSS) of mice that were inoculated 3 days previously with orthotopic 178-2 BMA cells, as described above. In selected experiments, AdIL-12 or Adbgal (1 Â 10 8 PFU/mouse) were injected intramuscularly 7 days after orthotopic tumor inoculation (4 days after splenocytes injection). In a model of pre-established metastases such as that occurs from intrasurgical seeding, mice received a tail vein injection of 178-2 BMA cells (25 000 cells in 100 ml of HBSS) at the same time as the splenocyte injection. For CD8 þ and/or CD4 þ cells depletion, splenocytes were treated with supernatants from the hybridomas 2.43 (anti-CD8) and GK1.5 (anti-CD4; TIB 210 and 207, respectively; ATCC) followed by rabbit complement-mediated lysis as previously described. 20 The effectiveness of depletion was verified by FACS. 18, 19 Animals were euthanized at the indicated times and underwent a careful necropsy for gross metastases. The primary tumor and spleen were removed and weighed. The spleen was placed in sterile medium until the splenocytes could be harvested to NK cell activity assays and CTL activity assays. The lungs were fixed by Bouins' solution and the number of metastases counted microscopically. The pelvic and retroperitoneal lymph nodes were excised, regardless of gross appearance, and along with a portion of the primary tumor processed for histological analysis. Samples of tissue were placed in formalin, paraffin embedded, cut into 4-5-mm sections, and stained with H&E for histological examination or immersed in TissueTec OCT medium and quick frozen in liquid N 2 .
All mice were maintained in facilities approved by the American Association for Accreditation of Laboratory Animal Care, and all animal studies were conducted in accordance with the principles and procedures outlined in the NIH's Guide for the Care and Use of Laboratory Animals.
Cytolytic assays
A tumor-specific cytolytic assay was performed 7 days after the splenocytes injection (10 days after the tumor inoculation). The spleen cells from treated mice (1.8 Â 10 7 cells/well) were cocultured with irradiated (10 4 rad) 178-2 BMA cells (15:1 responder:tumor cell ratio) in 4 ml of RPMI 1640 containing 50 mM 2-mercaptoethanol and 10% heat-inactivated FBS at 371C in a humidified atmosphere containing 5% CO 2 . At 1 day after culture initiation, mouse IL-2 (R&D systems, Minneapolis, MN) was added to the cultures to yield final concentrations of 20 U/ml. Cytotoxic effector lymphocytes were harvested after 5 days of incubation and used in a standard 51 Cr release assay to test the cytolytic activity of the effector cells. 22 Assays were performed in triplicate and the spontaneous lysis was o20% of the maximum release. NK activity was determined at several time points after treatment with 51 Cr-labeled YAC cells as the target cells. 16 
Statistical analysis
ANOVA was used to compare tumor weights. Survival analysis was with the log-rank test (Mantel-Cox test). All statistical analyses were performed with Statview 5.0 (SAS Institute Inc., Cary, NC).
Results
AdIL-12 and AdIL-12/B7 induce tumor growth suppression and CTL activity In this study, 178-2BMA mouse prostate cancer cells, that reproducibly metastasize with high frequency to bone, lymph nodes and lung following orthotopic inoculation, were used in a treatment model. [18] [19] [20] In situ gene therapy with AdIL-12 or AdIL-12/B7 inhibited local tumor growth in comparison with control group treated with Adbgal ( Figure 1a , P ¼ 0.0002). These results are consistent with our previous results with AdIL-12 or AdIL-12/B7 in situ gene therapy using orthotopic tumors initiated with RM-9 mouse prostate cancer cells. 16, 17 Demonstrable 178-2 BMA-specific CTL activities were obtained on day 7 after intratumoral injection with either AdIL-12 or AdIL-12/B7 (Figure 1b) . NK cell activities were not increased on day 7 (data not shown). Previous studies using the RM-9 model did not demonstrate CTL activity. 16, 17 The presence of systemic, that is, splenocyte, antitumor-specific immune cells suggested testing the ability to transfer this activity.
Adoptive splenocytes transfer suppresses tumor growth, inhibits spontaneous metastasis and improves survival We developed a model for adoptive splenocyte transfer using syngeneic mice bearing orthotopic tumors which can reflect a condition of local recurrence or residual tumor after radical therapy following neo-adjuvant in situ gene therapy. Splenocytes were obtained from mice harboring tumors generated by orthotopic injection of 178-2 BMA cells that had been treated in situ with AdIL-12, AdIL-12/B7 or Adbgal. The splenocytes contained 10-14% of CD8 þ lymphocytes and 19-28% of CD4 þ lymphocytes after 14-18 h culture; however, there was no difference in distributions of CD8 þ or CD4 þ lymphocytes in splenocytes of each group (data not shown). The splenocytes (1 Â 10 7 cells) were subsequently injected intravenously into syngeneic mice bearing orthotopic tumors generated 3 days previously by orthotopic inoculation with 178-2 BMA cells. Significant growth suppression of these orthotopic tumors was achieved with splenocytes derived from mice whose tumors had been injected with AdIL-12 compared to splenocytes from control Adbgal mice (P ¼ 0.0005) (Figure 2a) . Spontaneous lung metastases were also significantly suppressed with splenocytes derived from mice treated with AdIL-12/ B7 compared to splenocytes from control mice (P ¼ 0.0356) (Figure 2b) . A trend toward a reduction in lung metastases was also observed for splenocytes derived from the AdIL-12-treated group (P ¼ 0.1097). Improved survival was documented following adoptive splenocyte transfer in the AdIL-12 group (P ¼ 0.004) and in the AdIL-12/B7 group (P ¼ 0.009) relative to the control Adbgal group (Figure 2c ). Adoptive therapy for prostate cancer T Saika et al Cytolytic activities following adoptive splenocyte transfer Splenocytes harvested from the recipient mice 7 days following adoptive splenocyte transfer demonstrated increased levels of lytic activity against YAC cells from donor mice whose tumors had been injected with AdIL-12/B7 compared with splenocytes from mice with adoptive splenocytes from donor mice whose tumors had been injected with in situ AdIL-12 or Adbgal (Figure 3a) . 178-2 BMA-specific CTL activities were also detected in Both CD4 þ and CD8 þ T cells are required for adoptive therapy Identity of the effector cells in the in vivo antitumor activity (see Figure 2a ) was determined by in vitro depletion of specific T cells with antibody-mediated complement lysis (Figure 4 ). Depletion of both CD4 þ and CD8 þ cells in splenocytes obtained from mice whose orthotopic tumors had been treated with AdIL-12 prior to being used for adoptive therapy had an abrogated therapeutic response measured as orthotopic tumor weight at 14 days after orthotopic tumor initiation or 11 days after splenocyte injection (P ¼ 0.0142, compared to nondepleted splenocytes). The depletion of either CD4 þ or CD8 þ T cells independently was not sufficient to completely abrogate the response.
Enhancement of adoptive therapy with intramuscular AdIL-12
We explored the possibility that splenocyte transfer combined with systemic IL-12 delivery would have an additive or synergistic antitumor effector phase. As depicted in Figure 5a the tumor volume on day 12 after splenocyte injection (5 days after IM AdIL-12 or Adbgal injection) was significantly reduced by the combination of IM AdIL-12 with splenocytes from AdIL-12-treated animals (P ¼ 0.0086 compared to control IM Adbgal and Adbgal splenocytes). The effectiveness of this therapeutic approach was likely related to the enhancement of CTL activities as seen in Figure 5b . There was a significant increase in CTL activity in the AdIL-12 adoptive therapy group that also received IM AdIL-12 (P ¼ 0.0202 vs control Adbgal splenocytes and IM Adbgal). The IM AdIL-12 effect was also significant for the enhancement of AdIL-12 adoptive therapy (P ¼ 0.050 for IM Adbgal vs IM AdIL-12).
Adoptive transfer with intramuscular AdIL-12 suppresses lung metastasis In a model for metastatic spread due to intrasurgical seeding, we injected 178-2 BMA cancer cells IV at the time of adoptive transfer. Suppression of metastasis was seen in mice that received splenocytes from mice with Adbgaltreated tumors as well as IM AdIL-12; however, the reduction did not achieve significance (P ¼ 0.158) compared to those that received IM Adbgal ( Figure 6 ). The suppression lung metastases by adoptive transfer with splenocytes from mice whose prostate tumors were treated with AdIL-12 was confirmed with a significant reduction with IM AdIL-12 and Adbgal (P ¼ 0.0346 and 0.0331, respectively). Injection of splenocytes deleted of CD4 þ cells alone or CD8 þ cells alone showed a trend towards tumor growth suppression, but did not achieve statistical differences (P ¼ 0.2160 and 0.1277, respectively). Injection of splenocytes depleted of both CD4 þ and CD8 þ cells abrogated the antitumor effect (P ¼ 0.0142) (N ¼ 6-7 mice/group; bars ¼ s.e.). Adoptive therapy for prostate cancer T Saika et al
Discussion
In this study, we demonstrate the effectiveness of in situ gene therapy with adenoviral vector-mediated transduction of tumor cells with IL-12 or IL-12/B7 in a mouse prostate cancer model. Both vectors induced a tumorspecific CTL response detectable with splenocytes observed from treated animals. This was somewhat unexpected, as previous studies using RM-9 mouse prostate cancer cells together with AdIL-12 or AdIL-12/ B7 in a similar treatment model failed to demonstrate CTL. 16, 17 This difference may be related to the immunogenicity of 178-2 BMA cells compared to RM-9 cells and could be an important consideration for clinical applications. To extend the therapeutic potential of adenoviral vector-mediated IL-12 in situ gene therapy we evaluated the portability of the effector cells by using splenocytes for adoptive therapy. At 14 days following in situ gene therapy in this orthotopic prostate cancer model, splenocytes were isolated and cultured briefly then reinjected into mice with orthotopic tumors that had been initiated 3 days prior to adoptive transfer. Splenocytes derived from animal treated with either AdIL-12 or AdIL-12/B7 inhibited tumor growth, suppressed lung metastasis and improved long-term survival in this aggressive model (see Figure 2 ). Adoptive transfer of splenocytes from in situ AdIL-12-treated mice were more effective in orthotopic tumor control whereas AdIL-12/B7 generated more potent antimetastatic activities. This is likely a reflection of the more robust NK and CTL activities induced by adoptive transfer of splenocytes from mice treated with in situ AdIL-12/B7 (Figure 3 ). Both AdIL-12 and AdIL-12/B7 were equally effective at prolonging survival.
Combining adoptive therapy with in situ immunomodulatory gene therapy may be a very useful strategy for prostate cancer. Enhancement of a cellular immune response through the direct delivery of specific immunostimulatory cytokine genes into prostate tumors has antitumor and antimetastatic effects in preclinical models. [16] [17] [18] 20, 21 The in situ delivery of cytokine genes such as IL-12 that can promote Th1-mediated tumor cell cytotoxicity takes advantage of viable tumor cells at the site of treatment for maximal generation of tumor-associated antigens. Since peptides derived from the treated prostate cancer act as a vaccine, this approach can be termed in situ adenoviral vector-mediated gene-modified active vaccination. 23 This approach has the potential to generate a diverse array of tumor-associated antigens and therefore a variety of effector cells. This is particularly relevant for prostate cancer where tumor antigens have not been well defined. A diverse population of effector cells could potentially be expanded in vitro without defined antigens and subsequently used for adoptive therapy. 24, 25 Interestingly, it has been documented that IL-12 can upregulate inflammatory chemokines (i.e., IP10, MIG) and IFN-g under certain conditions. 26 Thus AdIL12 injection into prostate cancer could potentially stimulate specific chemokines/cytokines that would enhance trafficking of the adoptively transferred lymphocytes into the tumors and augment efficacy. This additional potentially synergistic activity should be the focus of future analyses in studies of this type.
Our results demonstrate that both CD4 þ and CD8 þ T cell have critical roles in the antitumor effect, that is, orthotopic tumor growth suppression induced by the adoptive therapy protocol. A previous study using AdIL-12 delivery into subcutaneous mouse colorectal adenocarcinoma CT26 tumors followed by isolation of T cells from draining lymph nodes 27 demonstrated that adoptive therapy required only CD8 þ T cells and not CD4 þ T cells. In contrast our results demonstrated that adoptively transferred CD4 þ T cells are also required. This may be a reflection of protocol differences since we isolated a more generalized population of cells from the spleen and did not utilize long-term coculture with tumor cells before adoptive therapy. Previous studies have shown that CD4 þ T cells can contribute to effective adoptive therapy in other models. 28, 29 We have shown that in situ adenoviral vector delivery of AdIL-12 or AdIL-12/B7 into RM-9 tumors increased the number of tumor-infiltrating CD4 þ T cells two-to three-fold compared to Adbgal. 17 We also cannot rule out the possibility that NK cells contribute to the therapeutic effect.
Our data provides evidence that adoptive immunotherapy could enhance the effectiveness of neo-adjuvant in situ IL-12 or IL-12/B7 gene therapy in cases of persistent malignancy. It is also worth noting that systemic delivery of the cytokine IL-12 via adenoviral IM delivery further enhanced the effectiveness. This increased activity was documented as significant suppression of orthotopic tumor growth that occurred only under conditions of adoptive splenocyte transfer from AdIL-12 treated animals with concomitant IM delivery of AdIL-12 ( Figure 5a ). Importantly, adjuvant IM AdIL-12 also significantly increased CTL activities in animals treated with adoptive splenocytes (Figure 5b ). Combination adoptive transfer of splenocytes from AdIL-12-treated animals and IM AdIL-12 also resulted in significant suppression of experimental metastases although these effects may be in part related to nonspecific immune activities resulting from IM adenoviral vector injection as IM Adbgal also produced significantly enhanced activities ( Figure 6 ).
In summary, the results of our study shows that adoptive transfer of splenocytes from animals bearing orthotopic mouse prostate cancer that received in situ AdIL12 gene therapy has therapeutic activities against newly generated orthotopic tumors and pre-established metastases. This activity appears to derive in part from significantly increased CTL activities that involve CD4 þ and CD8 þ T cells. Interestingly, our data also show that adjuvant IM AdIL-12 injection may augment these therapeutic activities. Although systemic recombinant IL-12 protein has limited clinical utility because of toxicity problems that were revealed in initial clinical trials, 30, 31 this alternative means of delivery may warrant further studies. It may also be useful to use this method of delivery, that is, adenoviral vector-mediated IM injection to introduce other stimulatory cytokines that have been previously shown to promote antitumor responses in the clinic, for example, IL-2. 32, 33 Our results have unique significance for neo-adjuvant and adjuvant immuno-gene therapy applications with standard treatments for presumed localized disease, that is, radical prostatectomy and radiation therapy. They also have significance for patients who may receive in situ immuno-gene therapy for recurrence after radiation therapy 13 as a way to enhance or prolong a favorable response. Additional preclinical and clinical studies are warranted to further investigate and optimize sequential in situ immuno-gene and adoptive immune cell therapy for prostate cancer and potentially other malignancies.
